Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to ...

已保存。查看收藏列表。 Investing.com - Cantor Fitzgerald在安进(NASDAQ:AMGN)商业表现超出预期后，重申了对该公司的"中性"评级，目标价为$305.00。根据InvestingPro分析，这家目前交易价格为$286.90的生物技术巨头在过去十二个月中展示了强劲的财务健康状况，收入增长达12.9%。 该研究公司强调了安进的强劲销售表现，特别是其Evenity ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $328.83, a 15.51% upside from current levels. In a report released yesterday, Citi also maintained a Hold ...